Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
Agios tested a new sickle cell medicine, but it didn't work well enough to keep making it, so they stopped. When a company stops developing a medicine, it usually means less hope for future sales, so investors watch to see what the company does next.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.